GRTX News and Press, Galera Therapeutics Inc. From 02/15/23

Clinical-stage biotech Galera Therapeutics ( NASDAQ: GRTX ) gained ~9% pre-market Wednesday after announcing that the FDA accepted and granted priority review for its marketing application for lead product candidate avasopasem. Filing the New Drug Application (NDA), Galera ( GRTX ...

PDUFA target date of August 9, 2023 Avasopasem would be first drug approved for SOM in patients with head and neck cancer MALVERN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and ...

MALVERN, Pa., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced...

MALVERN, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today ann...

Galera Therapeutics press release ( NASDAQ: GRTX ): Q3 GAAP EPS of -$0.60 misses by $0.13 . As of September 30, 2022, Galera had cash, cash equivalents and short-term investments of $42.8 million. Galera expects that its existing cash, cash equivalents and short-te...

Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 One-year ROMAN follow-up data presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting showed tumor outcomes and overall survival maintained compared to placebo One-year ROMA...

Tumor outcomes and overall survival maintained in patients with HNC at one-year Cisplatin-related chronic kidney disease reduced by 50% in avasopasem patients compared to placebo at one-year Meta-analysis of ROMAN and GT-201 (Phase 2b) supports efficacy across trials and...

MALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today an...

MALVERN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today an...

Biopharmaceutical company Galera Therapeutics ( NASDAQ: GRTX ) appointed Eugene Kennedy chief medical officer. Kennedy, who has served as chief medical officer at Innovative Cellular Therapeutics, will succeed Jon Holmlund. Holmlund will retire at 2022-end, a...